Market Place
Sourcing Support
Johnson & Johnson Seeks EMA Approval for IMBRUVICA® in MCL
18 Dec 2024 //
GLOBENEWSWIRE
AZ makes case for Calquence in another blood cancer type
17 Jun 2024 //
FIERCE PHARMA
IMBRUVICA Shows 10-Year Survival Benefit In First-Line CLL
14 Jun 2024 //
GLOBENEWSWIRE
Johnson & Johnson Announces Expansion of IMBRUVICA (ibrutinib) Label in the U.S.
26 Feb 2024 //
PRESS RELEASE
An Imbruvica combo regimen could have a new future in MCL
13 Dec 2023 //
FIERCE PHARMA
AbbVie`s Imbruvica-Brukinsa patent suit may have merit: expert
27 Jun 2023 //
FIERCE PHARMA
Ibrutinib Plus Chemoimmunotherapy Fails to Improve PFS in Pretreated FL, MZL
20 Jun 2023 //
ONCLIVE
Ibrutinib, Obinutuzumab, Venetoclax Triplet Elicits Clinical Benefit in MCL
19 Jun 2023 //
ONCLIVE
NICE signs off on AbbVie, J&J`s Imbruvica-Venclyxta combo in CLL
22 Apr 2023 //
FIERCE PHARMA
NICE gives green light to ibrutinib plus venetoclax for lymphocytic leukaemia
21 Apr 2023 //
PHARMIWEB
Bristol Myers, Pfizer, AbbVie drugs likely to face U.S. price negotiation
14 Mar 2023 //
REUTERS
BeiGene`s Brukinsa shows PFS benefit of 35% over Imbruvica
14 Dec 2022 //
BUSINESSWIRE
Oncternal Presents Data for Zilovertamab in Combination with Ibrutinib at ASH
10 Dec 2022 //
GLOBENEWSWIRE
Results from PIII Study of Fixed-Duration Treatment with IMBRUVICA show Efficacy
10 Dec 2022 //
PRNEWSWIRE
AbbVie Presents Data at ASH Adds to Robust IMBRUVICA® (ibrutinib) Science
10 Dec 2022 //
PRNEWSWIRE
ASH: BeiGene deals all-around blow to Imbruvica in CLL
22 Nov 2022 //
FIERCEPHARMA
BeiGene touts Brukinsa-Imbruvica head-to-head win in CLL
13 Oct 2022 //
FIERCEPHARMA
EMA makes new recommendations for Imbruvica
01 Oct 2022 //
ENPTS
U.S. FDA Approves IMBRUVICA as First & Only BTKi Treatment
25 Aug 2022 //
BIOSPACE
Children with Chronic Graft Versus Host Disease (cGVHD) May Now Be Prescribed IMBRUVICA® (ibrutinib)
24 Aug 2022 //
PRESS RELEASE
EC Approves IMBRUVICA in a Fixed-Duration Combination Regimen in CLL
04 Aug 2022 //
BUSINESSWIRE
In last Q2 with Humira market lock, AbbVie leans on best-seller
29 Jul 2022 //
FIERCEPHARMA
AbbVie pens Imbruvica pact to support pivotal Oncternal trial
16 Jul 2022 //
FIERCEBIOTECH
J&J gets EMA backing for Imbruvica-venetoclax combination
29 Jun 2022 //
FIERCEPHARMA
Oncternal Presents Plans for its PIII Study of Zilovertamab + Ibrutinib
10 Jun 2022 //
GLOBENEWSWIRE
New IMBRUVICA Data in Fixed-Duration Combination Regimen Presented at EHA 2022
10 Jun 2022 //
PRNEWSWIRE
J&J, AbbVie cancer drug significantly slows progression of rare lymphoma
04 Jun 2022 //
REUTERS
Oncternal Presents Updated Interim Data for Zilovertamab + Ibrutinib at ASCO
26 May 2022 //
GLOBENEWSWIRE
BRUKINSA Demonstrates Superior ORR Vs Ibrutinib in Analysis of ALPINE Trial
11 Apr 2022 //
BUSINESSWIRE
AbbVie Seeks New Indication for IMBRUVICA® in Pediatric Patients with cGVHD
28 Feb 2022 //
PRNEWSWIRE
J&J thinks it could have 14 new blockbusters by 2025
19 Nov 2021 //
REUTERS
J&J to divide into consumer health and pharmaceutical businesses
15 Nov 2021 //
PHARMACEUTICAL-TECHNOLOGY
Michael Landon’s daughter urges testing in pancreatic cancer PSA
08 Nov 2021 //
FIERCEPHARMA
Ibrutinib improves survival for younger people diffuse large B-cell lymphoma
04 Nov 2021 //
NIH
J&J science chief Stoffels to retire, adding to C-suite changes
13 Oct 2021 //
FIERCEBIOTECH
BeiGene`s Brukinsa challenges Imbruvica with latest lymphoma nod
15 Sep 2021 //
FIERCEPHARMA
AbbVie`s court win extends the life of blockbuster Imbruvica
31 Aug 2021 //
FIERCEPHARMA
AbbVie Says Court Rules Imbruvica Patents Valid in Generic Challenge
21 Aug 2021 //
MORNING STAR
Natco Pharma stock dips more than 4% over verdict on patent litigation
20 Aug 2021 //
INDIAINFOLINE
First-Line Ibrutinib/Venetoclax Better Than Chlorambucil/Obinutuzumab
18 Jun 2021 //
CANCERTHERAPYADVISOR
Data Showcasing Superiority of Zanubrutinib Over Ibrutinib: Presented at EHA
16 Jun 2021 //
BUSINESSWIRE
Imbruvica/Venclyxto tops Gazyva plus chemo in first-line CLL/SLL
15 Jun 2021 //
PHARMATIMES
IMBRUVICA + VENCLEXTA®/VENCLYXTO Proves Superior to Chlorambucil + Obinutuzumab
14 Jun 2021 //
PRNEWSWIRE
MBRUVICA® (ibrutinib)-Based Combination Regimen Proves Superior
14 Jun 2021 //
PRNEWSWIRE
AbbVie, J&J eye new Imbruvica CLL use in fixed-duration combo
14 Jun 2021 //
FIERCEPHARMA
Imbruvica/Venclyxto tops Gazyva plus chemo in first-line CLL/SLL
14 Jun 2021 //
PHARMATIMES
IMBRUVICA Plus VENCLEXTA/VENCLYXTO (venetoclax) Combination Positive Results
14 Jun 2021 //
PRESS RELEASE
First-Line Ibrutinib + Venetoclax Is Superior to Chlorambucil + Obinutuzumab
12 Jun 2021 //
PRNEWSWIRE
AbbVie, J&J eye new Imbruvica CLL use in fixed-duration combo
12 Jun 2021 //
FIERCE PHARMA
Phase 3 Study Results Show IMBRUVICA Shows Superior Progression-Free Survival
11 Jun 2021 //
BUSINESSWIRE
ALPINE Study Reveals Superior Safety and Efficacy of Zanubrutinib VS Ibrutinib
11 Jun 2021 //
PRNEWSWIRE
Phase 3 Study Results Show IMBRUVICA Shows Superior Progression-Free Survival
11 Jun 2021 //
BUSINESSWIRE
ALPINE Study Reveals Superior Safety and Efficacy of Zanubrutinib VS Ibrutinib
11 Jun 2021 //
PRNEWSWIRE
Abbvie`s APTIVATE study of Imbruvica Venclexta/Venclyxto Combo shows promise
08 Jun 2021 //
PHARMABIZ
Positive Data from CAPTIVATE Study IMBRUVICA Plus VENCLEXTA/VENCLYXTO
07 Jun 2021 //
PRNEWSWIRE
Calquence demonstrated fewer incidences of atrial fibrillation versus ibrutinib
07 Jun 2021 //
BUSINESSWIRE
